期刊文献+

多西他赛节拍化疗治疗老年晚期非小细胞肺癌疗效观察

Clinical observation of metronomic docetaxel chemotherapy to treat advanced non -small cell lung cancer in elderly patients
下载PDF
导出
摘要 目的探讨多西他赛单药节拍化疗一线治疗老年晚期非小细胞肺癌(NSCLC)的疗效及安全性。方法将20例老年晚期NSCLC患者作为节拍组(多西它赛25mg/m^2静脉滴注1h,第1、8、15天给药,每28天为1个周期),另20例为对照组(多西他赛75mg/m^2静脉滴注1h,第1天给药,每3周重复)。比较2组化疗2周期后的近期疗效、生活质量及毒性反应。结果节拍组近期疗效的有效率、临床受益率虽高于对照组,但差异无统计学意义(P〉0.05);节拍组患者化疗后生活质量改善情况优于对照组(P〈0.01),药物毒性反应较对照组轻(P〈0.05或P〈0.01)。结论多西他赛单药节拍化疗治疗老年晚期NSCLC患者安全有效,优于传统治疗方法。 Objective To explore the efficacy and safety of metronomic docetaxel monotherapy to treat advanced non - small cell lung cancer (NSCLC) in elderly patients. Methods Twenty elderly patients with advanced NSCLC were included into a treatment group who received metronomic docetaeel chemotherapy (through one hour of intravenous infusion with 25 mg/m^2 docetacel on Days 1,8 and 15, with a cycle length of 28 days). Meanwhile, another twenty patients were enrolled into a control group and given traditional docetaxel chemotherapy ( through one hour of intravenous infusion with 75 mg/m: docetacel on Day 1, which was repeated every three weeks). After two cycles of treatment, the short - term efficacy, quality of life and toxic reactions were compared between both groups. Results The treatment group presented a higher effective rate and better clinical benefit response (CBR) than the control group, in spite of no statistical difference ( P 〉 0.05 ). After metronomic therapy, the patients reported better quality of life ( P 〈 0.01 ) and less toxic reactions (P 〈 0.05 or P 〈 0.01 ) than those in the control group. Conclusion Metronomic doeetaxel chemotherapy is superior to the traditional regime with respect to its effectiveness and safely when applied to elderly patients with NSCLC.
出处 《徐州医学院学报》 CAS 2014年第10期665-668,共4页 Acta Academiae Medicinae Xuzhou
基金 徐州市科技局立项课题(XZD1-2010)
关键词 节拍化疗 多西他赛 非小细胞肺癌 老年 metronomic chemotherapy docetaxel non- small cell lung cancer elderly patients
  • 相关文献

参考文献16

二级参考文献60

  • 1鲁培,樊青霞,王丽萍,王留兴,高国谦.联合化疗对老年非小细胞肺癌生活质量的影响[J].医师进修杂志,2005,28(2):17-19. 被引量:10
  • 2刘基巍,陈俊霞,于丽华,田余祥,崔秀云,燕秋,富力.人参皂甙Rg3和核糖核酸酶抑制因子转基因对小鼠黑色素瘤的抑制作用研究[J].中华肿瘤杂志,2004,26(12):722-725. 被引量:30
  • 3王蓉,王宇岭,王庆才.多西紫杉醇联合顺铂及长春瑞滨联合顺铂治疗67例晚期NSCLC[J].中国肿瘤,2007,16(6):476-477. 被引量:3
  • 4Burris H A, Moore M J, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients advanced pancreas cancer randomized tridl [J]. Clin Oncol, 1997, 15: 2403.
  • 5Gridell C, Perrone F, Monfardini S. Lung cancer in the elderly[J]. EurJ Cancer, 1997, 33: 2313.
  • 6The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer[J]. J Natl Cancer Inst, 1999, 91(1): 66.
  • 7Earle C C, Tsai J S, Gelber R D, et al. Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis [ J ]. J Clin Oncol, 2001, 19(4): 1064.
  • 8Gridelli C, Aapro M, ArdizzoniA, et al. Treatment of advanced non-small celt lung cancer in the elderly: results of an international expert panel[ J ]. J Clin Oneol, 2005, 23 ( 13 ) : 3125.
  • 9Lilenbatan R C, Herndon J, Marcy L, et al. Single-agent (SA) versus combination chemotherapy (CC) in advanced non-small cell lung cancer(NSCLC) : a CALGB randomized trial of efficacy, quality of life (QQL) ,and cost-effectiveness [J]. Proceeding of ASCO, 2002, Abstract, No: 2.
  • 10GrideUi C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small cell lung cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase Ⅲ randomized trial[J]. JNatl Cancer Inst, 2003, 95(5): 362.

共引文献43

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部